Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 250 movers: CSR jumps as chip sales impress

Thu, 29th Oct 2009 12:11

CSR, which makes chips for Bluetooth and Global Positioning System (GPS) devices, is sharply higher after third quarter results were better than expected.Pre-tax profits for the period totalled $10.7m compared with a $30.8m over the same period the previous year. Revenues climbed to $219.9m from $205.5m. Bluetooth accounted for $150.4m, GPS for $59.5m.At the time of its second quarter results, CSR issued third quarter guidance of $195m to $215m for revenue. The median forecast of investment analysts' revenue forecasts was $208m.Qinetiq climbs after saying the boss of defence technology group QinetiQ, Graham Love, is being replaced by the former chief of banknote printer De La Rue, Leo Quinn, after eight years at the company.Investment management firm Evolution Group is going well after saying it expects to beat full year profit forecasts this year on the back of strong trading across all of its divisions. Revenues from the Investment Banking arm in the second half of 2009 will be at least double those seen in the first half, reflecting the increased corporate activity.Elsewhere in finance, Fund manager Henderson said assets under management increased 9% to £57.7bn in the third quarter to 30 September 2009 as market conditions continue to improve.National Express is sharply lower after the hard-up bus and train group said it has ended all takeover discussions with rival Stagecoach in order to focus on completing an equity fundraising by the end of this year.Shares in Yell fall back after the cash-strapped Yellow Pages directory publisher Yell Group again extended the deadline for its refinancing. The company, which is looking to restructure £3.8bn of debt, extended the deadline for the third time this week after last night's cut-off passed without success.FTSE 250 - RisersCSR (CSR) 446.60p +11.07%QinetiQ Group (QQ.) 154.80p +8.33%Taylor Wimpey (TW.) 37.77p +5.77%Aquarius Platinum Ltd. (AQP) 274.00p +5.71%Redrow (RDW) 139.80p +5.43%Evolution Group (EVG) 158.50p +4.55%Victrex (VCT) 784.50p +4.32%Barratt Developments (BDEV) 135.30p +4.24%BlueBay Asset Management (BBAY) 368.40p +3.98%Tomkins (TOMK) 162.60p +3.90%FTSE 250 - FallersNational Express Group (NEX) 328.10p -10.01%Laird (LRD) 163.20p -9.33%PartyGaming (PRTY) 221.50p -5.54%Henderson Group (HGG) 127.40p -4.64%PayPoint (PAY) 448.50p -4.17%Melrose Resources (MRS) 357.60p -2.85%Yell Group (YELL) 45.04p -2.81%Imagination Technologies (IMG) 202.50p -2.64%Debenhams (DEB) 77.50p -2.52%PV Crystalox Solar (PVCS) 65.55p -2.16%
More News
23 Nov 2020 17:37

IN BRIEF: Evgen Pharma Doses First Patient In Lead Candidate Trial

IN BRIEF: Evgen Pharma Doses First Patient In Lead Candidate Trial

Read more
23 Nov 2020 12:22

Evgen doses first patients in 'STAR' respiratory trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced on Monday that the first patient had now been enrolled and dosed in the 'STAR' trial of its 'SFX-01' treatment for acute respiratory infections.

Read more
11 Nov 2020 15:53

IN BRIEF: Evgen Pharma About To Begin SFX-01 Trial Recruitment

IN BRIEF: Evgen Pharma About To Begin SFX-01 Trial Recruitment

Read more
23 Oct 2020 11:49

Evgen gets full approval for SFX-01 trial in Covid-19 patients

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced on Friday that all necessary regulatory approvals had now been received for the 'STAR' trial of SFX-01 treatment for Acute Respiratory Infections.

Read more
23 Oct 2020 11:31

Shares In Evgen Pharma Rise On Approval For SFX-01 Trial

Shares In Evgen Pharma Rise On Approval For SFX-01 Trial

Read more
23 Oct 2020 10:46

UK WINNERS & LOSERS SUMMARY: Barclays Lifts FTSE's Lenders

UK WINNERS & LOSERS SUMMARY: Barclays Lifts FTSE's Lenders

Read more
24 Sep 2020 18:12

UK EXECUTIVE CHANGE SUMMARY: Carr's Names Pelham To Replace CEO Davies

UK EXECUTIVE CHANGE SUMMARY: Carr's Names Pelham To Replace CEO Davies

Read more
15 Sep 2020 22:08

UK TRADING UPDATE SUMMARY: Mortgage Advice Bureau Launches Later Life

UK TRADING UPDATE SUMMARY: Mortgage Advice Bureau Launches Later Life

Read more
15 Sep 2020 08:41

Evgen Pharma licences technology to Juvenescence

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the licensing of its sulforaphane stabilisation technology in a number of non-pharmaceutical applications to Juvenescence on Tuesday.

Read more
9 Jul 2020 16:16

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
17 Jun 2020 12:01

Evgen's 'SFX-01' to be tested with Covid-19 patients

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced its participation in the recently-notified funding initiative for Covid-19 clinical trials by the medical research charity LifeArc on Wednesday.

Read more
17 Jun 2020 10:42

Evgen Pharma Says SFX-01 To Be Evaluated In Covid-19 Trial

Evgen Pharma Says SFX-01 To Be Evaluated In Covid-19 Trial

Read more
15 Jun 2020 11:09

UK WINNERS & LOSERS SUMMARY: Bunzl Rises As It Sees Strong First Half

UK WINNERS & LOSERS SUMMARY: Bunzl Rises As It Sees Strong First Half

Read more
15 Jun 2020 10:24

Evgen Pharma Loss Slightly Wider On Expenses And Compensation

Evgen Pharma Loss Slightly Wider On Expenses And Compensation

Read more
15 Jun 2020 09:51

Losses widen as Evgen Pharma develops SFX-01

(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported a slight widening of its post-tax loss in its final results on Monday, to £2.7m, from £2.6m in the prior year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.